Annovis Bio Inc. Advances in Alzheimer’s Treatment and Corporate Growth

What is Annovis Bio Inc. focusing on with its Phase 3 trial?

Annovis Bio Inc. is focusing on early Alzheimer’s disease in its Phase 3 trial, with 76 secured U.S. sites, 46 actively enrolling, 38 patients dosed, and nearly 200 in screening, aiming to develop therapies for neurodegenerative diseases.

How is the enrollment progressing for Annovis Bio’s Phase 3 trial?

Enrollment is progressing on schedule with a 50% screen failure rate as expected, indicating steady progress towards the trial’s objectives.

What recent milestones has Annovis Bio achieved?

Recent milestones include presenting four scientific posters at AAIC 2025, hiring a director of biostatistics, hosting a trial update webcast, and securing global IP coverage for crystal buntanetap.

What are Annovis Bio’s financial results for Q2 2025?

As of June 30, 2025, Annovis Bio reported cash and equivalents totaling $17.1 million, up from $10.6 million at year-end 2024, with a narrowed net loss per share to $0.32 from $0.44.

Where can I find more information about Annovis Bio Inc.?

For more information, visit Annovis Bio’s website at www.annovisbio.com or follow them on LinkedIn, YouTube, and X. The latest news and updates are also available in the company’s newsroom at https://ibn.fm/ANVS.

What is the significance of Annovis Bio’s Phase 3 trial for Alzheimer’s disease?

The Phase 3 trial represents a critical step towards developing a potential treatment for early Alzheimer’s disease, addressing a significant unmet need in neurodegenerative diseases.

How does Annovis Bio’s financial improvement impact its research and development?

The improved financial results, including increased cash and equivalents and reduced net loss per share, provide Annovis Bio with greater resources to invest in its research and development efforts for neurodegenerative diseases.